The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers.
The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
The company, which is net debt free, reported a 37% jump in operational revenues for 2022 to ₹683.47 crore. Its profit after tax increased 33.73% in FY22 to ₹181.59 crore.
Capital, , and JP Morgan are the book-running lead managers.